Prior to joining Alacrita, Bill had been part of executive management teams and led the development of innovative anticancer drugs while in the role of Chief Medical Officer at AVEO Oncology and Merrimack Pharmaceuticals.
Earlier in his career, Bill held leadership and executive roles in large and small biopharma companies including Pfizer, Parke-Davis, Bristol-Myers Squibb, Hybridon and Burroughs-Wellcome. His responsibilities in these roles spanned clinical development, medical affairs, portfolio strategy and regulatory strategy, from preclinical development through to post-marketing trials and label extensions.
He has led programs through NDA and MAA approvals in various cancer types including GI stromal tumor, kidney and breast cancers. He has worked on small molecules, monoclonal antibodies, RNA-based therapeutics and oncolytic viruses.
Bill has a BA (Chemistry) and MD degrees from Case Western Reserve University, and a ScM degree in Clinical Investigation from Johns Hopkins University.
